JPRN-UMIN000036978已完成未知
A phase II trial of S-1 plus cisplatin with concurrent proton therapy for locally advanced NSCLC - A phase II trial of S-1 plus cisplatin with concurrent proton therapy for locally advanced NSCLC
agoya City West Medical Center0 个研究点目标入组 41 人开始时间: 2019年6月8日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 41
研究概览
简要总结
The 2- and 5-year OS were 77% (95% confidence interval 64%-89%) and 59% (43%-76%) The median OS was not reached. No grade 3 or higher radiation pneumonitis was observed.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)superior vena caval syndrome (2)Other cancers within 5 years (3)active and uncontrolled infection (4)Other serious complications (5)IP or IPF on X-p (6)pregnancy or lactation (7)portal vein tumor thrombosis (8)severe psychological disorders (9)malignant pleural effusion (10)uses fluoropyrimidine antineoplastic agent or flucytosine (11) cases in which the doctor is judged inappropriate for medical, psychological or other reasons other than the above (12)a coronary stent and aortic stent graft
研究者
相似试验
已完成
2 期
Phase II study of combination therapy of cisplatin suspension in lipiodol and 5-fluorouracil hepatic arterial infusion for advanced HCCHepatocellular carcinomaJPRN-UMIN000002073Division of Gastroenterology,Kurume University School of Medicine50
Unknown
2 期
Cisplatin,Docetaxel and S-1 for Advanced Gastric and Gastroesophageal Junction CancerGastroesophageal Junction CancerGastric CancerNCT01747707Chinese Academy of Medical Sciences40
已完成
2 期
S-1 and cisplatin with radiotherapy followed by durvalumab for locally advanced lung cancerung cancerLung cancerJPRN-jRCTs031190127Tanzawa Shigeru59
已完成
2 期
A phase II study of S-1 plus cisplatin with concurrent radiation for locally advanced thymic carcinoma (LOGIK1605/JART-1501)Thymic carcinomaJPRN-UMIN000024643Clinical Research Support Center Kyushu30
已完成
2 期
Phase II trial of SPM-011 + BNCT30 for recurrent malignant gliomaRecurrent malignant gliomaJPRN-jRCT2080224670STELLA PHARMA CORPORATIO27